Short answer
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 7.01 (Regulation FD Disclosure). Repligen merger remains subject to specified closing conditions, with BioLife becoming a wholly owned subsidiary.
BIOLIFE SOLUTIONS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Repligen merger remains subject to specified closing conditions, with BioLife becoming a wholly owned subsidiary
- Two-step merger structure: BioLife merges into Repligen subsidiaries, ultimately surviving entity becomes Repligen subsidiary
- August 3 employee video provides additional merger information, with transcript furnished as Exhibit 99.1
- Circulated employee email furnished as Exhibit 99.2, offering stakeholders additional transaction context
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOLIFE SOLUTIONS INC 8-K filings
Get the next BLFS 8-K as it lands
Follow BLFS for push alerts, or ask the research agent what this filing means.